Which roads lead to access? A global landscape of six COVID-19 vaccine innovation models

Globalization and Health
Adrián Alonso Ruiz1, Anna Bezruki2, Erika Shinabargar1, Kaitlin Large1, Marcela Vieira1, Iulia Slovenski1, Yiqi Liu1, Surabhi Agarwal1, Anna Becker1, Suerie Moon1
1Global Health Centre, Graduate Institute of International and Development Studies, Chem. Eugène-Rigot 2, Genève, 1202, Switzerland
2Georgetown University, 3700 O St NW, Washington, DC, 20057, USA

Tóm tắt

Abstract Background Unequal and inequitable access to Covid-19 vaccines in low- and middle-income countries (L&MICs) was a major political, ethical and public health failure in the pandemic. However, vaccine developers’ practices were not monolithic, but rather, took diverse approaches to supplying different countries, with important implications for global access. Results Using data on R&D investments, regulatory approvals, manufacturing and purchase agreements, and vaccine deliveries, we identified six distinct innovation models that apply across the 14 COVID-19 vaccines with more international presence from 2020–2022. “Western Early Arrivers” Pfizer/BioNTech and Moderna supplied the largest volumes quickly and prioritized high-income countries (HICs) from registration to vaccine delivery. “Western Latecomers” Janssen and Novavax supplied intermediate volumes later, also prioritizing HICs but with a greater proportion to L&MICs. “Major Chinese Developers” Sinopharm and Sinovac supplied intermediate volumes early, primarily to middle-income countries (MICs). “Russian Developer” Gamaleya completed development early but ultimately supplied small volumes, primarily to middle-income countries (MICs). “Cosmopolitan Developer” Oxford/AstraZeneca supplied large volumes early to HICs and MICs at the lowest prices. Finally, “Small MIC Developers” CanSino, Bharat Biotech, Medigen, Finlay Institute and the Center for Genetic Engineering and Biotechnology (CGEB), exported relatively small volumes to a few MICs. Low-income countries (LICs) were not targeted by any developer, and received far fewer doses, later, than any other income group. Almost all developers received public funding and other forms of support, but we found little evidence that such support was leveraged to expand global access. Conclusions Each of the six innovation models has different implications for which countries get access to which vaccines, how quickly, and at which prices. Each offers different strengths and weaknesses for achieving equitable access. Our findings also suggest that Western firms had the greatest capacity to develop and deliver vaccines quickly during the pandemic, but such capacity is rapidly becoming more globally distributed with MICs playing a significant role, especially in supplying other MICs. Given the critical role of public support in enabling pandemic vaccine development and supply, governments have both the capacity and responsibility to craft international rules that will make responses to future pandemics more equitable and effective.

Từ khóa


Tài liệu tham khảo

Suárez-Álvarez A, López-Menéndez AJ. Is COVID-19 vaccine inequality undermining the recovery from the COVID-19 pandemic? J Glob Health. 2022;12:05020.

United Nations Development Programme. UNDP Data Futures Platform. Impact of vaccine inequity on economic recovery. 2021. Available from: https://data.undp.org/vaccine-equity-archive/impact-of-vaccine-inequity-on-economic-recovery/. Cited 2023 Jul 27.

Cheong MWL, Allotey P, Reidpath DD. Unequal access to vaccines will exacerbate other inequalities. Asia Pac J Public Health. 2020. Available from: https://journals.sagepub.com/eprint/3WV4KHDEIBQNBFFYUADZ/full. Cited 2023 Jul 27.

Duroseau B, Kipshidze N, Limaye RJ. The impact of delayed access to COVID-19 vaccines in low- and lower-middle-income countries. Front Public Health. 2023;10:1087138.

Khetan AK, Yusuf S, Lopez-Jaramillo P, Szuba A, Orlandini A, Mat-Nasir N, et al. Variations in the financial impact of the COVID-19 pandemic across 5 continents: a cross-sectional, individual level analysis. EClinicalMedicine. 2022;44:101284.

Mahler DG, Yonzan N, Lakner C. The impact of COVID-19 on global inequality and poverty. World Bank: The World Bank; 2022. (Policy research working papers). Available from: https://elibrary.worldbank.org/doi/abs/10.1596/1813-9450-10198. Cited 2023 Jul 28.

Hotez PJ, Narayan KMV. Restoring vaccine diplomacy. JAMA. 2021;325(23):2337–8.

Peacocke E, Heupink LF, Frønsdal K, Dahl EH, Chola L. Global access to COVID-19 vaccines: a scoping review of factors that may influence equitable access for low and middle-income countries. BMJ Open. 2021;11(9):e049505.

Callaway E. The unequal scramble for coronavirus vaccines — by the numbers. Nature. 2020;584(7822):506–7.

Acharya KP, Ghimire TR, Subramanya SH. Access to and equitable distribution of COVID-19 vaccine in low-income countries. NPJ Vaccines. 2021;6(1):54.

Burki T. Global COVID-19 vaccine inequity. Lancet Infect Dis. 2021;21(7):922–3.

Figueroa JP, Hotez PJ, Batista C, Amor YB, Ergonul O, Gilbert SC, et al. Achieving global equity for COVID-19 vaccines: stronger international partnerships and greater advocacy and solidarity are needed. PLoS Med. 2021;18(9):e1003772.

Joseph S, Dore GJ. Vaccine Apartheid: a human rights analysis of COVID-19 vaccine inequity. papers.ssrn.com. Rochester; 2022. Available from: https://papers.ssrn.com/sol3/papers.cfm?abstract_id=4232624.

Katz IT, Weintraub R, Bekker LG, Brandt AM. From vaccine nationalism to vaccine equity - finding a path forward. N Engl J Med. 2021;384(14):1281–3.

Kavanagh MM, Gostin LO, Sunder M. Sharing technology and vaccine doses to address global vaccine inequity and end the COVID-19 pandemic. JAMA. 2021;326(3):219–20.

Lancet NT. Access to COVID-19 vaccines: looking beyond COVAX. Lancet. 2021;397(10278):941.

Loembé MM, Nkengasong JN. COVID-19 vaccine access in Africa: global distribution, vaccine platforms, and challenges ahead. Immunity. 2021;54(7):1353–62.

Moon S, Alonso Ruiz A, Vieira M. Averting future vaccine injustice. N Engl J Med. 2021;385(3):193–6.

Moon S, Agarwal S, Becker A, Ruiz AA. Embedding global access in development of future pandemic vaccines. BMJ. 2021;374:n2256.

Padma TV. COVID vaccines to reach poorest countries in 2023 - despite recent pledges. Nature. 2021;595(7867):342–3.

Sampat BN, Shadlen KC. The COVID-19 innovation system. Health Aff (Millwood). 2021;40(3):400–9.

Thambisetty S, McMahon A, McDonagh L, Kang HY, Dutfield G. The TRIPS intellectual property waiver proposal: creating the right incentives in patent law and politics to end the COVID-19 Pandemic. papers.ssrn.com. Rochester; 2021. Available from: https://papers.ssrn.com/sol3/papers.cfm?abstract_id=3851737.

Hunter DJ, Karim SSA, Baden LR, Farrar JJ, Hamel MB, Longo DL, et al. Addressing vaccine inequity — Covid-19 vaccines as a global public good. N Engl J Med. 2022;386(12):1176–9.

Khairi LNHM, Fahrni ML, Lazzarino AI. The race for global equitable access to COVID-19 vaccines. Vaccines. 2022;10(8):1306.

Peacock SJ. Vaccine nationalism will persist: global public goods need effective engagement of global citizens. Glob Health. 2022;18(1):1–11.

Pilkington V, Keestra SM, Hill A. Global COVID-19 Vaccine inequity: failures in the first year of distribution and potential solutions for the future. Front Public Health. 2022;10:821117.

Yamey G, Garcia P, Hassan F, Mao W, McDade KK, Pai M, et al. It is not too late to achieve global covid-19 vaccine equity. BMJ. 2022;376:e070650.

Kunyenje CA, Chirwa G, Mboma S, Ng’ambi W, Mnjowe E, Nkhoma D, et al. COVID-19 vaccine inequity in African low-income countries. Front Public Health. 2023;11:1087662.

Phelan A, Eccleston-Turner M, Rourke M, Maleche A, et al. Legal agreements: barriers and enablers to global equitable COVID-19 vaccine access. Lancet. 2020;396(10254):800–2.

Privor-Dumm L, Excler J, Gilbert S, Karim SAA, Hotez P, Thompson D, et al. Vaccine access, equity and justice: COVID-19 vaccines and vaccination. BMJ Glob Health. 2023;8(6):e011881.

Gonsalves G, Yamey G. The covid-19 vaccine patent waiver: a crucial step towards a “people’s vaccine.” BMJ. 2021;373:n1249.

Sekalala S, Forman L, Hodgson T, Mulumba M, Namyalo-Ganafa H, Meier BM. Decolonising human rights: how intellectual property laws result in unequal access to the COVID-19 vaccine. BMJ Glob Health. 2021;6(7):e006169.

Storeng KT, Stein F, Puyvallée ADB. COVAX and the many meanings of sharing. BMJ Glob Health. 2021;6(11):e007763.

Price WN, Rai AK, Minssen T. Knowledge transfer for large-scale vaccine manufacturing. Science. 2020;369(6506):912–4.

Usher AD. South Africa and India push for COVID-19 patents ban. Lancet. 2020;396(10265):1790–1.

Gaviria M, Kilic B. A network analysis of COVID-19 mRNA vaccine patents. Nat Biotechnol. 2021;39(5):546–8.

Meijer M, Verschuuren M, Weggen E. COVID-19 vaccines a global public good? Moving past the rhetoric and making work of sharing intellectual property rights, know-how and technology. Eur J Public Health. 2021;31(5):925–6.

Gold ER. What the COVID-19 pandemic revealed about intellectual property. Nat Biotechnol. 2022;40(10):1428–30.

Perehudoff K, Hoen ET, Mara K, Balasubramaniam T, Abbott F, Baker B, et al. A pandemic treaty for equitable global access to medical countermeasures: seven recommendations for sharing intellectual property, know-how and technology. BMJ Glob Health. 2022;7(7):e009709.

Gostin LO, Karim SA, Meier BM. Facilitating access to a COVID-19 vaccine through global health law. J Law Med Ethics. 2020;48(3):622–6.

Chatterjee N. Politics of vaccine nationalism in India: global and domestic implications. Available from: https://www.tandfonline.com/doi/epdf/10.1080/08039410.2021.1918238?needAccess=true. Cited 2023 Oct 6.

Nkengasong JN, Ndembi N, Tshangela A, Raji T. COVID-19 vaccines: how to ensure Africa has access. Nature. 2020;586(7828):197–9.

Moon S, Kickbusch I. A pandemic treaty for a fragmented global polity. Lancet Public Health. 2021;6(6):e355–6.

Stein F. Risky business: COVAX and the financialization of global vaccine equity. Glob Health. 2021;17(1):112.

Asundi A, O’Leary C, Bhadelia N. Global COVID-19 vaccine inequity: the scope, the impact, and the challenges. Cell Host Microbe. 2021;29(7):1036–9.

Sparke M, Levy O. Competing responses to global inequalities in access to COVID vaccines: vaccine diplomacy and vaccine charity versus vaccine liberty. Clin Infect Dis. 2022;75(Suppl 1):S86-92.

Usher AD. COVID-19 vaccines for all? Lancet. 2020;395(10240):1822–3.

Eccleston-Turner M, Upton H. International collaboration to ensure equitable access to vaccines for COVID-19: the ACT-Accelerator and the COVAX facility. Milbank Q. 2021;99(2):426–49.

Herzog LM, Norheim OF, Emanuel EJ, McCoy MS. COVAX must go beyond proportional allocation of covid vaccines to ensure fair and equitable access. BMJ. 2021;372:m4853.

Storeng KT, de Bengy Puyvallée A, Stein F. COVAX and the rise of the “super public private partnership” for global health. Glob Public Health. 2023;18(1):1–17. https://www.tandfonline.com/doi/full/10.1080/17441692.2021.1987502.

Usher AD. A beautiful idea: how COVAX has fallen short. Lancet. 2021;397(10292):2322–5.

Wouters OJ, Shadlen KC, Salcher-Konrad M, Pollard AJ, Larson HJ, Teerawattananon Y, et al. Challenges in ensuring global access to COVID-19 vaccines: production, affordability, allocation, and deployment. Lancet. 2021;397:1023–34. https://doi.org/10.1016/S0140-6736(21)00306-8.

de Bengy PA, Storeng KT. COVAX, vaccine donations and the politics of global vaccine inequity. Glob Health. 2022;18(1):26.

Usher AD. CEPI criticised for lack of transparency. Lancet. 2021;397(10271):265–6.

COVAX. COVAX: key learnings for future pandemic preparedness and response. COVAX; 2022. Available from: https://www.gavi.org/news-resources/knowledge-products/covax-key-learnings-future-pandemic-preparedness-and-response. Cited 2024 Jan 9.

Dzau VJ, Balatbat CA, Offodile AC. Closing the global vaccine equity gap: equitably distributed manufacturing. Lancet. 2022;399(10339):1924–6.

Kiszewski AE, Cleary EG, Jackson M, Ledley FD. NIH funding for vaccine readiness before the COVID-19 pandemic. Vaccine. 2021;39(17):2458–66.

Cross S, Rho Y, Reddy H, Pepperrell T, Rodgers F, Osborne R, et al. Who funded the research behind the Oxford–AstraZeneca COVID-19 vaccine? BMJ Glob Health. 2021;6(12):e007321.

Torreele E. Business-as-usual will not deliver the COVID-19 vaccines we need. Development. 2020;63(2–4):191. Society for International Development.

Swaminathan S, Pécoul B, Abdullah H, Christou C, Gray G, IJsselmuiden C, et al. Reboot biomedical R&D in the global public interest. Nature. 2022;602(7896):207–10.

Mazzucato M, Li HL. A market shaping approach for the biopharmaceutical industry: governing innovation towards the public interest. J Law Med Ethics. 2021;49(1):39–49.

Su Z, McDonnell D, Li X, Li X, Bennett B, Šegalo S, et al. COVID-19 vaccine donations—vaccine empathy or vaccine diplomacy? A narrative literature review. Vaccine. 2021;9(9):1024.

Liu Y. The global distribution of Chinese COVID-19 vaccines: a mix of politics and business. Geneva: Graduate Institute of International and Development Studies; 2022.

Suzuki M, Yang S. Political economy of vaccine diplomacy: explaining varying strategies of China, India, and Russia’s COVID-19 vaccine diplomacy. Rev Int Polit Econ. 2023;30(3):865–90.

Yamey G, Schäferhoff M, Kennedy K, Mao W. Preparing for pandemics such as coronavirus—will we ever break the vicious cycle of panic and neglect?. Brookings; 2020. Available from: https://www.brookings.edu/articles/preparing-for-pandemics-such-as-coronavirus-will-we-ever-break-the-vicious-cycle-of-panic-and-neglect/. Cited 2023 Aug 1.

Always fighting the last war? Post-Ebola reforms, blindspots & gaps in COVID-19. Geneva: Graduate Institute of International and Development Studies, Global Health Centre; 2021. Available from: https://repository.graduateinstitute.ch/record/299174.

Policy Cures Research. Landscape of emerging infectious disease research and development: from pandemic response to pandemic resilience. Australia; 2022. Report no.: 2. Available from: https://policy-cures-website-assets.s3.ap-southeast-2.amazonaws.com/wp-content/uploads/2022/06/16191104/2022-G-FINDER-EID-Report.pdf.

Sunyoto T, Vieira M, Moon S, Bezruki A. Knowledge portal on innovation and access to medicines. Research Synthesis: Biosecurity Research and Development (R&D); 2020. Available from: https://www.knowledgeportalia.org/biosecurityrd. Cited 2021 Aug 23.

Gross DP, Sampat BN. Crisis innovation policy from world war II to COVID-19. National Bureau of Economic Research; 2021. (Working paper series). Available from: https://www.nber.org/papers/w28915. Cited 2023 Jul 26.

Policy Cures Research. G-FINDER data portal. Available from: http://gfinder.policycuresresearch.org/. Cited 2023 Sep 10.

Naczyk M, Ban C. The Sputnik V moment: biotech, biowarfare and COVID-19 vaccine development in Russia and in former Soviet satellite states. East Eur Polit. 2022;38(4):571–93.

World Health Organization, Pan American Health Organization, European Commission. Cuban experience with local production of medicines, technology transfer and improving access to health. Geneva: World Health Organization; 2015. Available from: https://apps.who.int/iris/handle/10665/336685. Cited 2021 Oct 18.

Tancer RS. The pharmaceutical industry in Cuba. Clin Ther. 1995;17(4):791–8.

Naczyk M. Biotech, biodefense and COVID-19 vaccines in Russia’s national security state. Robert Schuman Centre for Advanced Studies: European University Institute; 2021. Available from: https://www.ssrn.com/abstract=3966243. Cited 2023 Aug 1.

Huneycutt B, Lurie N, Rotenberg S, Wilder R, Hatchett R. Finding equipoise: CEPI revises its equitable access policy | Elsevier Enhanced Reader. Vaccine. 2020;38:2144–8.

Global Health Centre. Knowledge portal on innovation and access to medicines. COVID-19 vaccines R&D investments. 2021. Available from: https://www.knowledgeportalia.org/covid-19-vaccine-r-d-funding. Cited 2023 Jul 28.

COVID-19 Market Dashboard | UNICEF Supply Division. Available from: https://www.unicef.org/supply/covid-19-market-dashboard. Cited 2022 Oct 14.

Khan T, Abimbola S, Kyobutungi C, Pai M. How we classify countries and people—and why it matters. BMJ Glob Health. 2022;7(6):e009704.

Fahrni ML, Ismail IAN, Refi DM, Almeman A, Yaakob NC, Saman KM, et al. Management of COVID-19 vaccines cold chain logistics: a scoping review. J Pharm Policy Pract. 2022;15(1):16.

World Health Organization. Status of COVID-19 vaccines within WHO EUL/prequalification evaluation process. 2023. Available from: https://extranet.who.int/prequal/sites/default/files/document_files/Status_COVID_VAX_08AUgust2023.pdf. Cited 2023 Oct 11.

Heidary M, Kaviar VH, Shirani M, Ghanavati R, Motahar M, Sholeh M, et al. A comprehensive review of the protein subunit vaccines against COVID-19. Front Microbiol. 2022;13:927306.

Medigen. MVC Covid-19 vaccine package insert. Medigen Vaccine Biologics Corp; 2023. Available from: https://www.medigenvac.com/en/research_vaccine_view.php?id=2.

Medigen Vaccine Biologics Corp. Medigen Vaccine Biologics reports positive results from 200-dose bag for mass vaccination of COVID-19 vaccines. Medigen Vaccine Biologics Corp.; 2022. Available from: https://www.medigenvac.com/en/news_view.php?id=139. Cited 2023 Oct 11.

World Health Organization. Interim recommendations for use of the Pfizer–BioNTech COVID-19 vaccine, BNT162b2, under Emergency Use Listing. 2022. Available from: https://www.who.int/publications-detail-redirect/WHO-2019-nCoV-vaccines-SAGE_recommendation-BNT162b2-2021.1. Cited 2023 Jul 28.

Toledo-Romaní ME, García-Carmenate M, Valenzuela-Silva C, Baldoquín-Rodríguez W, Martínez-Pérez M, Rodríguez-González M, et al. Safety and efficacy of the two doses conjugated protein-based SOBERANA-02 COVID-19 vaccine and of a heterologous three-dose combination with SOBERANA-Plus: a double-blind, randomised, placebo-controlled phase 3 clinical trial. Lancet Reg Health Am. 2023;18. Available from: https://www.thelancet.com/journals/lanam/article/PIIS2667-193X(22)00240-X/fulltext. Cited 2023 Jul 28.

CECMED. 2023. “CECMED. Clinical Trial Approval. Soberana 02.” Soberana 02. 2023. https://www.cecmed.cu/covid-19/aprobaciones/soberana-02.

Mendonça SA, Lorincz R, Boucher P, Curiel DT. Adenoviral vector vaccine platforms in the SARS-CoV-2 pandemic. NPJ Vaccines. 2021;6(1):1–14.

World Health Organization. Interim recommendations for use of the ChAdOx1-S [recombinant] vaccine against COVID-19 (AstraZeneca COVID-19 vaccine AZD1222 VaxzevriaTM, SII COVISHIELDTM). Available from: https://www.who.int/publications-detail-redirect/WHO-2019-nCoV-vaccines-SAGE_recommendation-AZD1222-2021.1. Cited 2023 Aug 10.

CIGB. CECMED. 2023. ABDALA Resumen de las Características del Producto. Available from: https://www.cecmed.cu/registro/rcp/biologicos/abdala-50-mg-vacuna-anti-covid-19-subunidad-proteica. Cited 2023 Aug 10.

Más-Bermejo PI, Dickinson-Meneses FO, Almenares-Rodríguez K, Sánchez-Valdés L, Guinovart-Díaz R, Vidal-Ledo M, et al. Cuban Abdala vaccine: effectiveness in preventing severe disease and death from COVID-19 in Havana, Cuba; a cohort study. Lancet Reg Health Am. 2022;16. Available from: https://www.thelancet.com/journals/lanam/article/PIIS2667-193X(22)00183-1/fulltext. Cited 2023 Jul 28.

World Health Organization. Interim recommendations for use of the Cansino Ad5-nCoV-S vaccine (Convidecia ®) against COVID-19. 2022. Available from: https://www.who.int/publications-detail-redirect/WHO-2019-nCoV-vaccines-SAGE-recommendation-Ad5-nCoV-Convidecia. Cited 2023 Jul 28.

COVID Product | ViewHub. Available from: https://view-hub.org/vaccine/covid/product. Cited 2023 Oct 11.

World Health Organization. COVID-19 Vaccine Explainer BBV152 COVAXIN. 2022.

World Health Organization. Interim recommendations for use of the Bharat Biotech BBV152 COVAXIN® vaccine against COVID-19. 2022. Available from: https://www.who.int/publications-detail-redirect/WHO-2019-nCoV-vaccines-SAGE-recommendation-bbv152-covaxin. Cited 2023 Jul 28.

World Health Organization. Interim recommendations for use of the Novavax NVX-CoV2373 vaccine against COVID-19: interim guidance, first issued 20 December 2021, updated 27 September 2022. World Health Organization; 2022. Report No.: WHO/2019-nCoV/vaccines/SAGE_recommendation/Novavax_NVX-CoV2373/2022.1. Available from: https://apps.who.int/iris/handle/10665/363204. Cited 2023 Jul 28.

Logunov DY, Dolzhikova IV, Shcheblyakov DV, Tukhvatulin AI, Zubkova OV, Dzharullaeva AS, et al. Safety and efficacy of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine: an interim analysis of a randomised controlled phase 3 trial in Russia. Lancet. 2021;397(10275):671–81.

World Health Organization. Interim recommendations for use of the inactivated COVID-19 vaccine, CoronaVac, developed by Sinovac. 2022. Available from: https://www.who.int/publications-detail-redirect/WHO-2019-nCoV-vaccines-SAGE_recommendation-Sinovac-CoronaVac-2021.1. Cited 2023 Jul 28.

Gote V, Bolla PK, Kommineni N, Butreddy A, Nukala PK, Palakurthi SS, et al. A comprehensive review of mRNA vaccines. Int J Mol Sci. 2023;24(3):2700.

World Health Organization. Interim recommendations for use of the Moderna mRNA-1273 vaccine against COVID-19. 2022. Available from: https://www.who.int/publications-detail-redirect/WHO-2019-nCoV-vaccines-SAGE-recommendation-mRNA-1273-2021.3. Cited 2023 Jul 28.

World Health Organization. Interim recommendations for the use of the Janssen Ad26.COV2.S (COVID-19) vaccine. 2022. Available from: https://www.who.int/publications-detail-redirect/WHO-2019-nCoV-vaccines-SAGE-recommendation-Ad26.COV2.S-2021.1. Cited 2023 Jul 28.

World Health Organization. Interim recommendations for use of the inactivated COVID-19 vaccine BIBP developed by China National Biotec Group (CNBG), Sinopharm. 2022. Available from: https://www.who.int/publications-detail-redirect/WHO-2019-nCoV-vaccines-SAGE-recommendation-BIBP. Cited 2023 Jul 28.

Global Health Centre. Knowledge portal. Russian COVID-19 vaccines. 2022. Available from: https://www.knowledgeportalia.org/russian-covid-19-vaccines. Cited 2023 Aug 2.

Open Media. Oткpытыe Meдиa. [The first Russian vaccine against coronavirus cost the federal budget 1.8 billion rubles]. 2020. Available from: https://openmedia.io/news/n4/pervaya-v-mire-vakcina-ot-koronavirusa-oboshlas-federalnomu-byudzhetu-v-18-mlrd-rublej/. Cited 2023 Aug 2.

Hotez PJ, Bottazzi ME. Whole inactivated virus and protein-based COVID-19 vaccines. Annu Rev Med. 2022;73(1):55–64.

Indian Ministry of Science & Technology. Augmentation of manufacturing capacity for COVAXIN production under Mission COVID Suraksha. 2021. Available from: https://pib.gov.in/pib.gov.in/Pressreleaseshare.aspx?PRID=1712271. Cited 2023 Aug 8.

Medigen Vaccine Biologics Corp. MVC and NIH collaborate to develop COVID-19 vaccine. Medigen Vaccine Biologics Corp; 2020. Available from: https://www.medigenvac.com/en/news_view.php?id=104. Cited 2023 Aug 8.

PRNewswire. Medigen’s COVID-19 vaccine combined with Dynavax’s CpG 1018 adjuvant receives Taiwan government subsidy with first participant dosed in early October. 2020. Available from: https://www.prnewswire.com/news-releases/medigens-covid-19-vaccine-combined-with-dynavaxs-cpg-1018-adjuvant-receives-taiwan-government-subsidy-with-first-participant-dosed-in-early-october-301150814.html. Cited 2023 Aug 8.

Osterholm M, Rabadán-Diehl C, Anzinger J, Bottazzi ME, Christie-Samuels C, Erondu N, et al. Insights from Cuba’s COVID-19 vaccine enterprise: report from a high level fact-finding delegation to Cuba. MEDICC Rev. 2022;24(3–4). Available from: https://mediccreview.org/executive-summary-insights-from-cubas-covid-19-vaccine-enterprise. Cited 2023 Oct 18.

Yaffe H. Cuba’s five COVID-19 vaccines: the full story on Soberana 01/02/Plus, Abdala, and Mambisa | LSE Latin America and Caribbean. LSE Latin America and Caribbean blog. 2021. Available from: https://blogs.lse.ac.uk/latamcaribbean/2021/03/31/cubas-five-covid-19-vaccines-the-full-story-on-soberana-01-02-plus-abdala-and-mambisa/. Cited 2023 Sep 5.

2022 Access to Medicine Index | Access to Medicine Foundation. accesstomedicinefoundation.org. Available from: https://accesstomedicinefoundation.org/resource/2022-access-to-medicine-index.

Actualización de la estrategia para el desarrollo de las vacunas cubanas – Sitio oficial de gobierno del Ministerio de Salud Pública en Cuba. Available from: https://salud.msp.gob.cu/actualizacion-de-la-vacunacion-en-el-marco-de-los-estudios-de-los-candidatos-vacunales-cubanos-y-la-intervencion-sanitaria/. Cited 2023 Sep 6.

The cost of one dose of the Sputnik V vaccine will be less than $10 for international markets. Available from: https://sputnikvaccine.com/newsroom/pressreleases/the-cost-of-one-dose-will-be-less-than-10-for-international-markets/. Cited 2023 Sep 6.

Pandemic Transparency. Health Justice Initiative (HJI). 2023. Available from: https://healthjusticeinitiative.org.za/pandemic-transparency/. Cited 2023 Sep 6.

Kapczynski A. The political economy of market power in pharmaceuticals. J Health Polit Policy Law. 2023;48(2):215–39.

BioSpace. The rise, fall and future of Novavax. Available from: https://www.biospace.com/article/the-rise-fall-and-future-of-novavax-/. Cited 2023 Sep 7.

Suspension of supply of COVID-19 vaccine (COVAXIN®). Available from: https://www.who.int/news/item/02-04-2022-suspension-of-supply-of-covid-19-vaccine-covaxin. Cited 2023 Oct 16.

Florio M, Gamba S, Pancotti C. Mapping of long-term public and private investments in the development of COVID-19 vaccines. IP/A/COVI/2022-03. European Parliament. COVI Committee; 2023.

Cohen J. Unveiling ‘Warp Speed’, the White House’s America-first push for a Coronavirus vaccine. Science. 2020. https://doi.org/10.1126/science.abc7056.

U. S. Government Accountability. GAO@100. Operation warp speed: accelerated COVID-19 vaccine development status and efforts to address manufacturing challenges. Available from: https://www.gao.gov/products/gao-21-319. Cited 2021 Aug 23.

O’Neill Institute for National & Global Health Law. Equitable access review of CEPI’s COVID-19 vaccine development agreements. 2022. Available from: https://cepi.net/wp-content/uploads/2022/05/EQUITABLE-ACCESS-REVIEW-OF-CEPIS-COVID-19-VACCINE-DEVELOPMENT-AGREEMENTS_Final_April-2022.pdf. Cited 2023 Aug 8.

Thông tin
Thông tin xuất bản

Globalization and Health

Thông tin tác giả